IMMP vs LLY
Valuation
Profitability
Growth
Financial Health
Dividends
AI Verdict
Immutep Limited presents a high-risk profile characterized by a Piotroski F-Score of 4/9, indicating only marginal financial stability. While the company shows strong YoY revenue growth of 91.50% and maintains a healthy current ratio of 2.97, these are overshadowed by a catastrophic operating margin of -763.71% and a total collapse in share price. The stock has lost approximately 78% of its value over the last year and 88.8% in the last month, signaling a severe lack of market confidence and a bearish technical trend of 0/100.
LLY shows neutral fundamentals based on deterministic rules. Financial strength is weak (F-Score 3/9). Mixed signals with both opportunities and risks present.
Compare Another Pair
Related Comparisons
IMMP vs LLY: Head-to-Head Comparison
This page compares Immutep Limited (IMMP) and Eli Lilly and Company (LLY) across key fundamental metrics including valuation ratios, profitability margins, growth rates, financial health indicators, and dividend metrics. Each metric highlights the better-performing stock so you can quickly identify relative strengths and weaknesses.
Our AI engine independently analyzes each company's financials, competitive position, and market conditions to produce a verdict (Bullish, Neutral, or Bearish) along with key strengths and risks. Use this comparison alongside your own research to make informed investment decisions.